In vitro mitogenic activation is widely used to investigate the functiona! properties of human peripheral blood celts. The evaluation of mitogenic responsiveness is especially of interest in cases of immunodeticiency. Most often mitogens such as the plant lectins phytohaemagglutinin (PHA), pokeweed mitogen (PWM). and concanavalin A (Con A) are used. Staphylococcus protein A (SpA). a protein present in the cell wall oC many Siaphylococcu.s aureus strains, can also be used to study mitogenic responsiveness [18. 28] .
Incorporation of PH]thymidine by the proliferating cells is often used to measure the responsiveness of mononuclear cells (MNC) to these mitogens. Using this technique, it is not easy to investigate which specific cell subset responds.
Approaches that have been used to determine which cells proliferate include separation of subpopulations either before or after in vitro culture by cell sorting, panning, or lysis [19. 25. 28, 32] . Other approaches make use of double-marker analysis of single cells. In this way the simultaneous presence of both certain differentiation markers and cell activation markers, such as HLA-DR. the transferrin receptor, and the IL-2 receptor, can be demonstrated [6, 17. 30] . However, these activation markers are probably not restricted to proliferating cells [20] .
Definite markers lor cell proliferation are those markers which arc only expressed during specific phases of the cell cycle, e.g. the Ki-67 antigen and PCNA [8. 9. 21] . DNA content can also be regarded as a marker for eell cycle phase [5, 22] , Furthermore, cells in S phase of the cell cycle can incorporate the thymidine analogue 5'-bromo-2'-deoxyuridine (BrdU). which can be detected by anti-BrdU monoclonal antibodies (MoAb) [4. 11. 24) . Finally, metaphase cells can be regarded as the best marker for the M phase of cell cycle.
We here describe two methods to determine the immunoiogical phenolype of proliferating cells: BrdU incorporation and metaphases as markers for prolileration. We investigated which cells proliferate after stimulation with PHA. PWM. Con A. and SpA.
MATERIALS AND METHODS
Isolation iijnwmnnulear (.ells. Periphcfitl blood (PB) MNC were obtained from hep;irinized venous blood of six healthy volunteers, aged 25 .15 years, by Fieoll Paque (1,077 g/cm"; Pharmacia. Uppsala. Sweden) density cenlrifugation. Cells were washed twice in RPMI 1640 cuhure medium wilhoul Hepes. supplemented wiih L-glutamincH mM) penicillin (100 lU/ml). streplomycin(50/jg/ml).and \5"'<-< heat-inaclivated fetal calFserum (FCS), The KCS was specifically selected for its growth-supporting properties and low endogenous mitogenic activity.
Iniiminohgiiul marker analysis. To detect surface membrane markers, the cells were incubated with optimally titrated relevant MoAb as described [33] Immtinolo^icLiI marker analysis of nwlupbase cells. MNC from twodonors were cultured wiih PHA or SpA for 2. 3. 4. 5. and 6 days. Cells were centrifuged and resuspended at a concentration of lO' cells/ml, Fifly microlitres of the cell suspensions was incubated at room icmpcrature with 50 /il of the relevant MoAb, After 15 min the cells were washed twice and 50 /d ofa tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse Ig antiserum (Central Laboratory of the Blood Transfusion Service) was added; to arrest the cells in melaphase 0,25 /ig Colcemid (Gibco Laboratories) was added. After another 15 min the eells were washed in a hypotonic KCl solution (O,O75M)and cytocentrifuge preparations were made (Nordic Immunological Laboratories. Tilburg. The Netherlands), The slides were put in atebrinc (Gurr. Poole. UK) dissolved inethanol 70"ii (vol/vol) for 10 min to fix the cells and to stain DNA, The alebrine staining was evaluated by using the same filter combination as used for KITC. and the expression of (he immunoiogical markers was evaluated by using a TRITC filler combination [33] , When possible, up to 100 metaphase cells were evaluated for each immunoiogical marker. The percentage of ceiis in metaphase was determined by screening 2000 MNC, BrclV incorptiration mul immunnlogiialmarker analysis iif BrdU^ cells. MNC from ihe same four donors as were used for the [ni]thymidine incorporation experiment were cultured with PlIA. Con A. PWM. or SpA for 2. 3. 4. 5. 6. and 7 days. To label ihe cells in ihe S phase of the cell cycle. BrdU (Sigma) was added to a final concentration of 10 /iM. 30 min before harvesting. After harvesting, cells were washed twiee. incubated with MoAb for 30 min to label a surface membrane marker, and washed again. Subsequently 50 ^1 of a goal-anti-mouse Ig antiserum conjugated with colloidal gold particles of 5 nm size was added (Janssen Pharmaceulica. Beerse. Belgium), After 30 min the cells were washed twice and a cytocentrifuge preparation was made. The slides were air-dried. fl,xed in ethanol 70% (vol/vol) for 30 min. and denatured in NaOH 0,07 Mfor 2 min. After washing in Na;H>BO,i. the slides were incubated with a FITC-conjugated anti-BrdU MoAb (Beclon Dickinson) for 30 min in a moisl chamber. After two washings the immunogold-labelled slides were subjected to a silver enhancement procedure as specified by Jans.sen Pharniiicciitica. We used a silver development lime or25 min, lor ihe visualization oflhe silver granules we used diii-illuminatioii or. in ihe case of weak slaining. epi-illuminaliori wiih polari/aliori fillers. The percentage of cells having incorporated BrdU was determined by screening 400 MNC. For double-marker analyses with ditTerentlaiion markers 200 BrdU^ cells were evaluated.
After 6 days of culture cells were tested for cyiophismic Ig (Cylg) expression as previously described |3.'^]. Cytocentrifuge preparations were simultaneously incubated wiih an FITC-conjugated burro anti-human Iglambdii antiserum and a TRITC-coiijugaled goat antihuman Ig-kappa antiserum (Kallestad Laboratories, Austin, Tex,, USA).
RESULTS

Immunological marker analysis
The MNC Iraclion from Ihe PB of all donors contained 5-10% B cells (CD20\ CD37*). 50 6O' M> T cells (CO3 +) with a CD4/CD8 ratio which varied from I.I to 1.8. <\'Vu granulocytic cells (CD I 5 * K and I 5-25% monocytic cells (CD 14 '). In addition, about lO";. of (he cells were positive for NK markers such as CD16 (Leu-llb) and CD57 (Leu-7), The percentages of positivity for HLA-DR reflected the sum of B cells and monoeytic cells. Cells expressing CD7I (translerrin receptor) and/or CD25 (IL-2 reeeplor) were only detected at levels of < l"/.i.
f'HJlhymidine imoiporalion
The results of ['Hjthymidine ineorporation on mitogenic stimulation are summarized in Fig, 1 . left. Each point represents the median count from values obtained in four donors. The kinetics found in the four donors were similar lo the kinetics shown in the compilation. The maximum PHA-indueed ['HJthymidine incorporation was found on days 3-5 (71.000-84,000 cpm). For Con A, maximum incorporation was found on day 4 in all donors (56.000-71.000 cpm). After PWM stimulation the maximum incorporation (23,000 52.000 cpm) was found on day 4 in one donor and on days 6 and 7 in the other three donors. For SpA the maximum incorporation was found on days 5 and 6 (63,000 113.000 cpm). Without the addition oi mitogens, ['H]thymidine ineorporation was < 1000 cpm up today 5 and < 3000cpm on days 6 and 7.
di^icul marker analysis of melaphase
The results of the immunological marker analysis of metaphases after stimulation with PHA and SpA are summarized in 
BrdU incorporalion and immunological marker analysis of BrdU' cells
The results of the incorporation of BrdU and the immunological marker analysis of BrdU* cells after stimulation with PHA. Con A, PWM. and SpA are summarized in Fig. I, right, and Fig.  3 respeetively. Eaeh point represents the median of the results obtained in four donors. The kinetics found in the four donors were quite similar. Maximum stimulation, i.e. the highest percentage of cells in S phase of the cell cyele, was found for Con A on day 2. for PHA on day 3. for PWM on day 7. and for SpA on day 6 (Fig. 1,  right) . First we tried to label the surface membrane differentiation markers with a TRITCconjugated antibody, however, probably because of the denaturation and fixation procedure necessary for visualization of BrdU, the TRITC signal was too weak. Therefore immunogold labelling with silver enhancement was used for labelling the surfaee membrane markers.
In all but one donor PHA and Con A gave rise to more CD8 • than CD4-proliferating eells. In addition, distinct proliferation of B cells was observed on days 3 and 4 of PHA culture, while B-eell proliferation after Con A stimulation was minimal (Fig. 3. upper part) . Stimulation with PWM resulted mainly in proliferation of T cells, whieh were slightly more often CD4 • than CD8', and to a lesser extent in proliferation of B cells (Fig. 3. lower left) . Upon stimulation with SpA inalldonors the majority of the proliferating cells was CD4'. B-cell proliferation was observed on days 2 and 3 only (Fig, 3. lower right) .
Determination of other markers revealed that on all days of culture NK markers such as CDI6 and CD57 were expressed on about 10'!'., of the proliferating eells after PHA or Con A stimulation and about 5% of those eells after stimulation with PWM or SpA.
Activation markers were expressed by the BrdU' eells as well as BrdU" eells. These markers were not expressed by all BrdU"^ cells. Positivily for HLA-DR on Ihe BrdU^ eells was found in roughly the same pereentages as positivity for CD20. indieating that these HI_A-DR\ BrdU ' cells were probably proliferating B cells. CD71 (transferrin receptor) atid CD25 (IL-2 receptor) were found on 60-80'^ of the BrdU ĉ ells on day 3 and 30-60"n of the BrdU ' cells on day 7. Without the addition oK mitogens <^\"As of BrdU ' cells were seen on days 2-6. On day 7 of the cultures. 2' Mi of BrdU ' eells were found in two donors, while in the other two donors about 7".> of the cells had incorporated BrdU. Labelling o'i the eells revealed that on dav 3 about 35"ii of the BrdU+ eells were B cells and aboul 50";> were T cells. In addition some monocytic cells (CDI4^) and NK cells {CDI6^ CD57 + } were proliferating. On day 7 the majority of the proliferating eells was CD4 T cells.
To investigate whether cells coexpressed CD4 and CDS. as has been reported by others [2, 30] . double-marker analysis for these two markers was performed in two donors. It was not possible to perform a triple immunological marker analysis for BrdU and these two T-cell markers. In all cultures CD4'. CD8' cells were seen, however mostly the percentages were I "<i or lower. In one donor, about 2'''i) of CD4 ' CDS* eells were seen 6 days after stimulation with PHA.
After 6 days of stitnulation with PWM about 1-5% of the MNC expressed Cylg. in the cultures stimulated with PHA. ConA. or SpA, and in the eultures without a mitogen. the proportion o{ Cylg* cells was less than 0.1 "'';i.
DISCUSSION
We here describe two diiferent methods to determine the immunological phenotype of proliferating eells. The method which enables itnmunological marker analysis of metaphase cells was originally developed to combine cytogenetic analysis and immunologieal marker analysis at the single-eel! level [13] . Using this method we found that PHA is a better mitogen for CD8 * PBMNC Ihan for CD4' PBMNC. while SpA mainly stimulates CD4-^ eells. To confirm this finding and to eompare the kineties of PHA and SpA with those of Con A and PWM. we used a technique whieh was less laborious and whieh enables the analysis of eells in S phase of the eeil cyele, i.e. a double-marker analysis for BrdU ineorporation and a differentiation marker.
Using the BrdU method, maximum percentages of cells in S phase were found on day 2 for Con A and on day 3 for PHA {Fig i. right). On the other hand, using ['H]thymidine incorporation. the kineties for these two mitogens seemed to he different. The maximum incorporation for Con A and PHA was found on day 4 and day 5 respectively (Kig 1. left). This discrepancy is readily explained, since [*H]thymidine incorporation is measured over the whole population of eells, while in the BrdU technique the percentage of cells in S phase is determined. Owing to the rise in the tolal cell number during culture, the absolute number of proliferating eells is maximal on day 4 or day 5 in Con A and PHA cultures, while the maximum proportion of proliferating cells is already found by day 2 or day 3 respeetively. For SpA and PWM this discrepancy was not observed, probably because of the fact that the proliferation peak oeeurs at a later stage (day 5-6), when the culture medium becomes exhausted.
The results of the immunological marker analysis of BrdU' eells after PHA and SpA stimulation confirmed the results obtained by the metaphase technique. The preponderance of CD8^ proliferating eells over CD4*^ proliferating others using different methods [3. 6. 30] . Con A also appeared to stimulate more CD8+ eells than CD4 ' cells. This is in contrast with the tindings of Persson & Johansson [25] . However, they separated the T-cell subsets prior to mitogenic stimulation. A major difference between PHA and Con A was the finding of a signifieant B-eell proliferation upon PHA stimulation, whieh was minimal after Con A stimulation. B-eell proliferation by PHA has previously been reported [4. 22, 23] . Interestingly this PHA-indueed B-eell proliferation took place early (days 3 and 4). which suggests a direct effect of PHA on B eells and whieh supports the application of PHA to the culture of malignant B eells [26] , On the other hand, this early stimulation of B cells might be induced by early release of eytokines.
PWM is often used as a mitogen to test T-cell proliferation as well as T cell-dependent B-cell proliferation, but it turned out to stimulate primarily Teells. This eonfirms previous reported data [30] . In contrast to PHA and Con A, slightly moreCD4* cells than CDS'" eells were proliferating in the PWM eultures.
SpA appeared to be a potent T-cell mitogen. accompanied by some B-cell proliferation on day 3. Jaeoh & Rose [18] suggested using SpA as a mitogen for studying human T-eell funetion, however they did not test whieh T-eell subsets were proliferating. The consistent preponderance of CD4^ over CD8* proliferating eells is in contrast to the results obtained with the other mitogens. Based on discontinuous bovine serum albumin density-gradient fractionation experiments, Sakane & Green [28] found that SpAresponsive T eells in human PB were different from the eells that respond to PHA. However. they did not perform immunologieal marker analysis.
Since SpA is such a potent mitogen for CD4"' celU. it is interesting to use SpA for in vitro funetional studies aimed at testing the proliferative capacity of this T-eell subset. It is well known that HIV type I infects and destroys CD4 • cells [7. 12] , Deereased in vitro lymphocyte proliferative responses are well known in HIV-1-infected individuals and AIDS patients [29, 31] . The poor response of MNC from AIDS and pre-AIDS patients is not only aseribed to a deereased number of CD4* cells, but the responsiveness of these eeils also seems to be deficient [10. 16] . Publications on the use of SpA in funetional studies of the MNC from HIV-infeeted persons are stilt laeking. Recently. Hofmann c/ al. [\5\ described the application of the mitogen-stimulated lymphoeyte transformation response as a predictive marker for the development of AIDS and AlDS-related symptoms in persons infected with HIV. They found that, by comparing PHA, Con A. and PWM as mitogens, the risk of a worsened clinical condition was 55 times higher in seropositive men with a decreased PWM response than in other seropositive men. Later on, reduction of the proliferative responses to PHA and Con A took place. This sequential decrease in responsiveness to PWM, Con A, and PHA was also observed by Radvany ei al. [27] , but nol by Alcoeer-Varela ci al. [1] . Hofmann el al. [14] explained this phenomenon by an at least partly preserved funetion of the PHA CD2-dependent pathway. On the other hand, our data revealed that, in eontrast to PHA and Con A, PWM stimulates more CD4' eells than CD8' eells. However. SpA turned out to be an even better mitogen for CD4* cells. Therefore, it may be rewarding to inelude SpA in funetional studies of HIV-infeeted persons.
